A
Aulos Bioscience
Innovative IL-2 therapeutics transforming cancer care with computationally designed monoclonal antibodies
About Aulos Bioscience
Aulos Bioscience is an innovative company in the field of immuno-oncology, which focuses on using the body's immune system to fight cancer. The company is pioneering the development of IL-2 (Interleukin-2) therapeutics, a type of treatment that aims to boost the immune system's ability to combat cancer cells. Their main product, AU-007, is a monoclonal antibody designed using advanced computational methods. This product is unique because it selectively targets a specific part of IL-2, which helps activate the immune system more effectively against tumors.
Read full description
Aulos Bioscience primarily serves patients battling various forms of cancer. The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources. Their business model revolves around research and development (R&D) of new cancer therapies, conducting clinical trials to prove their effectiveness and safety, and eventually bringing these therapies to market.
The company makes money through a combination of funding from investors, partnerships with other biotech firms, and potentially, future sales of their approved therapies. Currently, Aulos is in the clinical trial phase, specifically in Phase 2 of their Phase 1/2 clinical program for AU-007. This phase is crucial for demonstrating the safety and efficacy of their product before it can be approved for wider use.
Aulos Bioscience is driven by a strong commitment to scientific rigor and a mission to extend the lives of cancer patients. Their approach is characterized by the use of computational design to create highly specific and effective treatments, which they believe will change the landscape of cancer care.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 75.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Aulos Bioscience.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2023 | $20M | $200M | Apple Tree Partners | ↗ |
| SERIES AOther financing | Jan 2021 | $40M | $160M | Apple Tree Partners | — |
Growth signals
Latest recorded traffic for Aulos Bioscience is 2.4K monthly website visits, up 9.1% over the last three months. Aulos Bioscience's team grew 15.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Apple Tree Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aulos Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aulos Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.